文献速递白血病

儿童急性髓系白血病原发化疗耐药的遗传机制

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.
PubMed 文献 · Leukemia · 2019-02-13

作为TARGET计划的一部分,对诱导化疗失败的儿童急性髓系白血病进行了全基因组DNA及转录组RNA和miRNA测序分析。研究识别出至少三个诱导失败遗传亚组:NUP98重排、无NUP98突变的WT1体细胞突变、以及KMT2C和MLLT10等复发变异。化疗前后比较显示基因表达程序不变,但克隆演化多样,包括FRMD8、DHX32、PIK3R1、SHANK3、MKLN1突变等位基因选择,WT1和TP53突变克隆持续,FLT3、PTPN11和NRAS突变克隆消除。

要点

  • 诱导失败儿童AML存在至少三个遗传亚组:NUP98重排、WT1突变、KMT2C/MLLT10变异。
  • 化疗前后基因表达程序不变,但克隆演化呈现多种形式。
  • 化疗后选择FRMD8、DHX32、PIK3R1、SHANK3、MKLN1突变,WT1/TP53克隆持续,FLT3/PTPN11/NRAS克隆消除。

核心结论

  • 研究刻画了儿童AML原发化疗耐药的遗传机制,应有助于改进其诊断和治疗策略。

研究设计与样本

  • 作为TARGET计划的一部分,对诱导化疗失败的儿童AML进行全基因组DNA及转录组RNA和miRNA测序分析。

主要发现

  • 识别出至少三个诱导失败遗传组:NUP98重排、无NUP98突变的WT1体细胞突变、以及KMT2C和MLLT10等复发变异。
  • 化疗前后标本比较显示基因表达程序不变,但化疗后呈现多种克隆演化。
  • 克隆演化包括FRMD8、DHX32、PIK3R1、SHANK3、MKLN1突变等位基因选择,WT1和TP53突变克隆持续,FLT3、PTPN11和NRAS突变克隆消除。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemias (AML) are characterized by mutations of tumor suppressor and oncogenes, involving distinct genes in adults and children. While certain mutations have been associated with the increased risk of AML relapse, the genomic landscape of primary chemotherapy-resistant AML is not well defined. As part of the TARGET initiative, we performed whole-genome DNA and transcriptome RNA and miRNA sequencing analysis of pediatric AML with failure of induction chemotherapy. We identified at least three genetic groups of patients with induction failure, including those with NUP98 rearrangements, somatic mutations of WT1 in the absence of apparent NUP98 mutations, and additional recurrent variants including those in KMT2C and MLLT10. Comparison of specimens before and after chemotherapy revealed distinct and invariant gene expression programs. While exhibiting overt therapy resistance, these leukemias nonetheless showed diverse forms of clonal evolution upon chemotherapy exposure. This included selection for mutant alleles of FRMD8, DHX32, PIK3R1, SHANK3, MKLN1, as well as persistence of WT1 and TP53 mutant clones, and elimination of FLT3, PTPN11, and NRAS mutant clones. These findings delineate genetic mechanisms of primary chemotherapy resistance in pediatric AML, which should inform improved approaches for its diagnosis and therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. McNeer NA, Philip J, Geiger H, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019. PMID: 30760869. doi:10.1038/s41375-019-0402-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。